ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2034

A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)

Mihir D. Wechalekar1, Steve Quinn2, Susan Lester3, Ella Shanahan4, Robert Metcalf5, E. Michael Shanahan6 and Susanna Proudman4,7, 1Flinders University School of Medicine, Adelaide, Australia, 2Flinders Clinical Effectiveness, Flinders University, Adelaide, Australia, 3Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, 4University of Adelaide, Discipline of Medicine, Adelaide, Australia, 5University of Adelaide, Adelaide, Australia, 6Rheumatology, Flinders University, Bedford Park, South Australia, Australia, 7Department of Rheumatology, Royal Adelaide Hospital, SA, Australia

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and treatment, Work Disability

  • Tweet
  • Email
  • Print
Session Information

Session Title: Epidemiology and Public Health (ACR): Rheumatoid Arthritis Pathogenesis and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose

Historical data (1)indicate a third of patients with RA are unable to work within the first 5 years of diagnosis. Our aim was to quantify work disability in an inception cohort of patients with early (<12 months) RA (fulfilling ACR 1987 revised classification criteria) receiving treat-to-target combination DMARD therapy. 

Methods

Patients received initial triple therapy (methotrexate, sulfasalazine and hydroxychloroquine) with escalation (using other DMARDs or biologic DMARDs) to achieve DAS28(ESR) remission. Patients completed an annual validated work and arthritis questionnaire. Random effect mixed modelling was used to assess associations between the primary outcome, average hours worked per week, and baseline prognostic factors, with subject entered as a random effect to account for correlated observations. Hours worked per week (HWPW) were compared with age, gender and period matched population averages.

Results

There were 541 observations on 139 patients. Patients were included in the analysis if they had complete data and were working at any time point, that is, those with at least one positive value for hours worked; this included 67 patients with 313 observations. The mean (SD) age at disease onset was 42.8 (11.0) years; 55/67 (82%) were women; median (IQR) duration of polyarthritis was 16 (12-28) weeks. The median (IQR) follow up time was 3 (2.0-5.2) years.  At baseline, the proportion of patients in work at baseline was 67% and this did not significantly change with time (73% at the end of the follow-up period).

Males worked more hours; there was no significant loss of working hours over the mean follow-up period (Table 1).  Anti-cyclic citrullinated peptide antibody positivity was associated with loss of working hours; there was no relationship between baseline or area-under-the-curve DAS28 and HAQ and working hours lost. When examined by profession 50% working as labourers on enrolment gave up work on follow up as compared to only 7% of those in managerial roles. For the matched population averages HWPW increased by 3.7 over a comparable follow-up period (p=0.001).

Table 1.

 

p-value

Males worked 14.5 (95% CI 6.4, 22.6) hours/ week more than females

<0.001

Patients with anti-cyclic citrullinated peptide (CCP) positivity were more likely [7.4 (95%CI 1.3, 13.7)] to reduce working hours

0.017

Loss of working hours over mean follow-up period was 0.85 (95%CI -1.65, 3.4)

0.52

Conclusion

In contrast to the era before the advent of more intensive treatment approaches, a treat-to-target strategy mainly using conventional DMARDs preserves work capacity in patients with RA over the first few years of disease. Patients with ACPA or in manual labouring roles were more likely to reduce working hours.

(1) Barrett EM et al. Rheumatology 2000;39:403-09.


Disclosure:

M. D. Wechalekar,
None;

S. Quinn,
None;

S. Lester,
None;

E. Shanahan,
None;

R. Metcalf,
None;

E. M. Shanahan,
None;

S. Proudman,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-treat-to-target-strategy-preserves-work-capacity-in-early-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences